Efficacy and safety of suvratoxumab for prevention of Staphylococcus aureus ventilator-associated pneumonia (SAATELLITE): a multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2 pilot trial.

[1]  B. Giraudeau,et al.  Prevention of Early Ventilator-Associated Pneumonia after Cardiac Arrest. , 2019, The New England journal of medicine.

[2]  Harald Rouha,et al.  Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Study of the Penetration of a Monoclonal Antibody Combination (ASN100) Targeting Staphylococcus aureus Cytotoxins in the Lung Epithelial Lining Fluid of Healthy Volunteers , 2019, Antimicrobial Agents and Chemotherapy.

[3]  H. Goossens,et al.  Comparison of GeneXpert MRSA/SA ETA assay with semi-quantitative and quantitative cultures and nuc gene-based qPCR for detection of Staphylococcus aureus in endotracheal aspirate samples , 2019, Antimicrobial Resistance & Infection Control.

[4]  K. Asehnoune,et al.  Safety and tolerability of a single administration of AR-301, a human monoclonal antibody, in ICU patients with severe pneumonia caused by Staphylococcus aureus: first-in-human trial , 2018, Intensive Care Medicine.

[5]  P. Póvoa,et al.  Antibiotic consumption and ventilator-associated pneumonia rates, some parallelism but some discrepancies. , 2017, Annals of translational medicine.

[6]  R. Wunderink,et al.  International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia , 2017, European Respiratory Journal.

[7]  John T. Menchaca,et al.  Ultra-Short-Course Antibiotics for Patients With Suspected Ventilator-Associated Pneumonia but Minimal and Stable Ventilator Settings , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  N. Eldridge,et al.  Trend in Ventilator-Associated Pneumonia Rates Between 2005 and 2013. , 2016, JAMA.

[9]  C. Thomson,et al.  Management of Adults with Hospital-acquired and Ventilator-associated Pneumonia. , 2016, Annals of the American Thoracic Society.

[10]  H. Jafri,et al.  Safety, Tolerability, and Pharmacokinetics of MEDI4893, an Investigational, Extended-Half-Life, Anti-Staphylococcus aureus Alpha-Toxin Human Monoclonal Antibody, in Healthy Adults , 2016, Antimicrobial Agents and Chemotherapy.

[11]  B. François,et al.  Molecular quantification of bacteria from respiratory samples in patients with suspected ventilator-associated pneumonia. , 2016, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[12]  Margaret A Dudeck,et al.  Antimicrobial-Resistant Pathogens Associated With Healthcare-Associated Infections: Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011–2014 , 2016, Infection Control & Hospital Epidemiology.

[13]  M. Bonten,et al.  The SAATELLITE and EVADE Clinical Studies Within the COMBACTE Consortium: A Public-Private Collaborative Effort in Designing and Performing Clinical Trials for Novel Antibacterial Drugs to Prevent Nosocomial Pneumonia. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  Herren Wu,et al.  Mechanisms of Neutralization of a Human Anti-α-toxin Antibody* , 2014, The Journal of Biological Chemistry.

[15]  J. Suzich,et al.  Assessment of an Anti-Alpha-Toxin Monoclonal Antibody for Prevention and Treatment of Staphylococcus aureus-Induced Pneumonia , 2013, Antimicrobial Agents and Chemotherapy.

[16]  D. Annane,et al.  Early-Onset Ventilator-Associated Pneumonia in Adults Randomized Clinical Trial: Comparison of 8 versus 15 Days of Antibiotic Treatment , 2012, PloS one.

[17]  C. Malone,et al.  Alpha-Toxin Induces Programmed Cell Death of Human T cells, B cells, and Monocytes during USA300 Infection , 2012, PloS one.

[18]  S. Foster,et al.  Staphylococcus aureus Induces Eosinophil Cell Death Mediated by α-hemolysin , 2012, PloS one.

[19]  J. Wehland,et al.  Functional Antibodies Targeting IsaA of Staphylococcus aureus Augment Host Immune Response and Open New Perspectives for Antibacterial Therapy , 2010, Antimicrobial Agents and Chemotherapy.

[20]  A. Shorr,et al.  Ventilator-associated pneumonia: the clinical pulmonary infection score as a surrogate for diagnostics and outcome. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  Jordi Rello,et al.  A European care bundle for prevention of ventilator-associated pneumonia , 2010, Intensive Care Medicine.

[22]  A. Anzueto,et al.  Economic Burden of Ventilator-Associated Pneumonia Based on Total Resource Utilization , 2008, Infection Control & Hospital Epidemiology.

[23]  K. Zou,et al.  Receiver-Operating Characteristic Analysis for Evaluating Diagnostic Tests and Predictive Models , 2007, Circulation.

[24]  D. Cook,et al.  Evidence-Based Clinical Practice Guideline for the Prevention of Ventilator-Associated Pneumonia , 2004, Annals of Internal Medicine.

[25]  H. Hemilä.  Vitamin C intake and susceptibility to pneumonia. , 1997, The Pediatric infectious disease journal.

[26]  J. Vincent,et al.  The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure , 1996, Intensive Care Medicine.

[27]  W. Knaus,et al.  APACHE II: a severity of disease classification system. , 1985 .

[28]  M. Bonten,et al.  Staphylococcus aureus colonization at ICU admission as a risk factor for developing S. aureus ICU pneumonia. , 2017, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[29]  B. Menzies,et al.  Staphylococcus aureus alpha-toxin induces apoptosis in endothelial cells. , 2000, FEMS immunology and medical microbiology.